Gonçalves Ocílio Ribeiro, Dominici Saul, Monteiro Júlia Dos Santos, Weba Elizabet Taylor Pimenta, Hong Anthony, Santos Ana Beatriz, Camarotti Maria Tereza, Pacheco Niels, de Oliveira João Victor Araújo, Junior Arlindo Bispo da Silva, Ferreira Márcio Yuri, Almeida Kelson James
Federal University of Piauí, Teresina, PI, Brazil.
Federal University of Maranhão, São Luís, MA, Brazil.
Curr Probl Cardiol. 2025 Mar;50(3):102950. doi: 10.1016/j.cpcardiol.2024.102950. Epub 2024 Dec 1.
Chagas Disease (CD) poses significant health risks, including an increased incidence of acute ischemic stroke (AIS). However, the specific risk factors for AIS in CD patients are not well-defined. This meta-analysis aims to identify clinically relevant risk factors for AIS in individuals with CD.
We performed a systematic review and meta-analysis by searching PubMed, Embase, Web of Science, and the Cochrane Library up to August 2024. Primary outcomes evaluated in AIS patients with CD included reduced left ventricular ejection fraction (LVEF), anticoagulation therapy, atrial fibrillation (AF), left ventricular apical aneurysm (LVAA), pacemaker use, and coronary artery disease (CAD). Risk ratios (RRs) and odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using a random-effects model.
Six studies were included, involving 1,229 patients (48% male). The analysis revealed a higher risk of AIS in CD patients with reduced LVEF (RR 3.38; 95% CI 1.38 - 8.27), AF (OR 4.85; 95% CI 2.13 - 11.02), LVAA (OR 3.76; 95% CI 1.96 - 7.21), and pacemaker use (OR 2.37; 95% CI 1.38 - 4.09). Anticoagulation therapy was associated with a reduced likelihood of stroke (OR 0.28; 95% CI 0.19 - 0.41). No significant association was found between CAD and stroke risk (OR 1.56; 95% CI 0.93 - 2.59).
Reduced LVEF, AF, LVAA, and pacemaker use are correlated with higher stroke incidence in CD patients, while anticoagulation therapy diminishes this risk. Further randomized studies are needed to refine AIS prevention strategies for this population.
恰加斯病(CD)带来重大健康风险,包括急性缺血性卒中(AIS)发病率增加。然而,CD患者发生AIS的具体危险因素尚不明确。本荟萃分析旨在确定CD患者发生AIS的临床相关危险因素。
我们通过检索截至2024年8月的PubMed、Embase、Web of Science和Cochrane图书馆进行了系统评价和荟萃分析。在患有CD的AIS患者中评估的主要结局包括左心室射血分数(LVEF)降低、抗凝治疗、心房颤动(AF)、左心室心尖部动脉瘤(LVAA)、起搏器使用和冠状动脉疾病(CAD)。使用随机效应模型计算风险比(RRs)和比值比(ORs)以及95%置信区间(CIs)。
纳入六项研究,涉及1229例患者(48%为男性)。分析显示,LVEF降低的CD患者发生AIS的风险更高(RR 3.38;95% CI 1.38 - 8.27)、AF(OR 4.85;95% CI 2.13 - 11.02)、LVAA(OR 3.76;95% CI 1.96 - 7.21)和起搏器使用(OR 2.37;95% CI 1.38 - 4.09)。抗凝治疗与卒中可能性降低相关(OR 0.28;95% CI 0.19 - 0.41)。未发现CAD与卒中风险之间存在显著关联(OR 1.56;95% CI 0.93 - 2.59)。
LVEF降低、AF、LVAA和起搏器使用与CD患者较高的卒中发病率相关,而抗凝治疗可降低此风险。需要进一步的随机研究来完善针对该人群的AIS预防策略。